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Mutations in SLC30A10 Cause Parkinsonism
and Dystonia with Hypermanganesemia,
Polycythemia, and Chronic Liver Disease
Marialuisa Quadri,1 Antonio Federico,2 Tianna Zhao,1 Guido J. Breedveld,1 Carla Battisti,2
Cathe´rine Delnooz,3 Lies-Anne Severijnen,1 Lara Di Toro Mammarella,2 Andrea Mignarri,2 Lucia Monti,4
Antioco Sanna,4 Peng Lu,5 Francesca Punzo,1,6 Giovanni Cossu,7 Rob Willemsen,1 Fabrizio Rasi,8
Ben A. Oostra,1 Bart P. van de Warrenburg,3 and Vincenzo Bonifati1,*
Manganese is essential for several metabolic pathways but becomes toxic in excessive amounts. Manganese levels in the body are
therefore tightly regulated, but the responsible protein(s) remain incompletely known. We studied two consanguineous families with
neurologic disorders including juvenile-onset dystonia, adult-onset parkinsonism, severe hypermanganesemia, polycythemia, and
chronic hepatic disease, including steatosis and cirrhosis. We localized the genetic defect by homozygosity mapping and then identified
two different homozygous frameshift SLC30A10 mutations, segregating with disease. SLC30A10 is highly expressed in the liver and
brain, including in the basal ganglia. Its encoded protein belongs to a large family of membrane transporters, mediating the efflux of
divalent cations from the cytosol. We show the localization of SLC30A10 in normal human liver and nervous system, and its depletion
in liver from one affected individual. Our in silico analyses suggest that SLC30A10 possesses substrate specificity different from its closest
(zinc-transporting) homologs. We also show that the expression of SLC30A10 and the levels of the encoded protein are markedly
induced by manganese in vitro. The phenotype associated with SLC30A10 mutations is broad, including neurologic, hepatic, and
hematologic disturbances. Intrafamilial phenotypic variability is also present. Chelation therapy can normalize the manganesemia,
leading to marked clinical improvements. In conclusion, we show that SLC30A10 mutations cause a treatable recessive disease with
pleomorphic phenotype, and provide compelling evidence that SLC30A10 plays a pivotal role in manganese transport. This work
has broad implications for understanding of the manganese biology and pathophysiology in multiple human organs.Introduction
Manganese (Mn) is one of the most abundant elements
on earth, an essential trace metal in biology, and necessary
for several metabolic pathways and cellular homeostasis.1
Manganese becomes toxic when present in excessive
amounts. Manganese levels in the body are therefore
tightly regulated, but the responsible protein(s) and path-
ways remain incompletely known.2
In normal conditions, most manganese amounts are
absorbed in the intestine from dietary intake and excreted
by the liver in the biliary system.1 Manganese intoxication
might occur in different contexts, such as professional
heavy exposure in miners, smelters, and welders;3 in indi-
viduals with chronic liver disease due to the failure of
manganese hepatic clearance;4 and in individuals under-
going prolonged total parenteral nutrition, if excessive
manganese amounts by-pass the hepatic filter and enter
the bloodstream.5 More recently, manganese intoxica-
tion has been reported in drug-addicts exposed to this
metal as a contaminant of the amphetamine-like drug
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The AmeDuring manganese intoxication the metal accumulates
in the liver, muscle, and brain, particularly in the basal
ganglia (globus pallidus and substantia nigra), and causes
a neurologic disorder (manganism) characterized by early
behavioral disturbances (also referred to as manganese
madness) and a subsequent, prominent extrapyramidal
syndrome, bearing similarities to dystonia (MIM 128100)
and Parkinson disease (MIM 168600) (manganese-induced
parkinsonism).8,9
The familial occurrence of severe hypermanganesemia
and hepatic cyrrhosis, in combination with an extrapyra-
midal motor disorder and polycythemia, was described in
2008 in two young individuals born from consanguineous
parents and suggests an autosomal-recessive disorder (MIM
613280).10 At least two other isolated individuals with
similar phenotypes have been reported.11,12 Interestingly,
in these individuals not only were all the known causes
and contexts of manganese intoxication excluded, but
the blood manganese levels were also much higher than
those occurring in individuals with manganese intoxica-
tions due to known causes. These considerations suggest
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Figure 1. Clinical and Neuroimaging Findings in Individuals with SLC30A10 Mutations
(A and G) Pedigrees of the Italian and the Dutch families. Black symbols denote affected individuals. The proband is indicated with
an arrow.
(B–F) BrainMRI images in the individuals from the Italian family. In both brothers marked T1 hyperintensities, typically seen in persons
with manganese intoxication, are present in MTC T1-weighted images in the globus pallidus, putamen, caudate nucleus, midbrain, and
cerebellum, bilaterally (axial [B–C] and sagittal [E–F] images in individual SIE-03 [B and E] and SIE-02 [C and F]. In (D), a 3DFFET1-
weighted, coronal oblique multiplanar reconstruction image shows hyperintensity along the cerebello-rubro-thalamic pathways in
individual SIE-03.
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metabolism, leading to hypermanganesemia and accumu-
lation and secondary toxicity in the liver, bone marrow,
and the nervous system. Here we report two unrelated
families with this syndrome and the identification of reces-
sive mutations in SLC30A10 (MIM 611146) as the disease
cause.
Subjects and Methods
We studied two white consanguineous families (one of Italian and
one of Dutch descent) with multiple affected siblings; a pattern
compatible with autosomal-recessive inheritance (Figure 1). There
was no history of neurological, hepatic, or hematological diseases
in the previous generations. The parents of the affected individ-
uals could not be personally examined by us because they were
dead or unavailable. The study was approved by the appropriate
institutional review board, and written informed consent was
obtained from all subjects.
DNA Studies
Genomic DNA was isolated from peripheral blood with standard
protocols. We performed genome-wide homozygosity mapping
in three affected individuals (two from the Italian family and
one from the Dutch family). Genome-wide genotyping was per-
formed with the Illumina HumanOmniExpress BeadChip arrays
(730,525 SNPs at a median distance of 2.1 kb). Homozygosity
mapping was performed with GenomeStudio 2011,V2011.1
(Illumina, San Diego, CA) and Nexus Copy Number, Discovery
Edition, ver. 5.1 (BioDiscovery, El Segundo, CA).
We then performed exome sequencing in one Dutch affected
individual (NIJ005, IV-3 in Figure 1G) by using in-solution
capturing (Agilent SureSelect Human All Exon 50Mb Kit, Agilent
Technologies, Santa Clara, CA) and Illumina HiSeq, paired-end
sequencing, at an average of 303 coverage. Reads were aligned to
the human reference genome (hg19 assembly) with the Burrows-
Wheeler-Aligner (BWA, version 0.5.9c). Single-nucleotide variants
and small insertions and deletions (indels) were annotated with
the Genome Analysis Tool Kit (GATK, version 1.0.5777).
Last, we sequenced all the exons and exon-intron boundaries of
one positional candidate (SLC30A10) by using Sanger protocols.
Primers and PCR protocols are reported in Table S1, available
online. The variants detected were tested in ethnically matched
healthy controls by Sanger sequencing. The SLC30A10 vari-
ants are named according to the GenBank accession numbers
(NM_018713.2 and NP_061183.2) and numbered at nucleotide
level from the ‘‘A’’ of the ATG-translation initiation codon.
Immunohistochemistry
Human brain and spinal cord tissues were obtained from The
Netherlands Brain Bank, Netherlands Institute for Neuroscience,
Amsterdam, The Netherlands. Human normal liver tissue was
obtained from the Department of Pathology, Erasmus MC,
Rotterdam. All material has been collected from donors from
whom a written informed consent for autopsy and the use of
the material and clinical information for research purposes had
been obtained. We also studied specimens from a liver biopsy per-(H and I) Brain MRI images in the individuals from the Dutch fam
T1-weighted images in the globus pallidus, bilaterally (coronal imag
the time the manganese blood levels had returned at almost
shown in [I]).
The Ameformed in 1981 in one affected individual from the Dutch family
with SLC30A10 mutations (NIJ012, IV-2 in Figure 1G).
For immunohistochemistry, paraffin-embedded sections (7 mm)
were analyzed from the cerebral cortex, globus pallidus, cere-
bellum, and spinal cord of two normal male donors (their ages
at death were 76 and 81 years). Briefly, dewaxed sections were
pretreated for antigen retrieval by pressure cooking in 0.1 M
sodium citrate buffer (pH 6) for 5 min. Subsequently, an indirect
immunoperoxidase labeling was performed with goat polyclonal
antibody against SLC30A10 (Santa Cruz, 1/50) as a primary
antibody and anti-goat conjugated with HRP (1/100; DAKO) as a
secondary antibody. Sections were counterstained with heamatox-
ylin and mounted with entellan.
Cell Culture and Immunoblotting
HepG2 (hepatocellular carcinoma) cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) (Lonza) supple-
mented with 10% fetal calf serum, 50 U/ml penicillin and
50 mg/ml streptomycin, in a humidified 5% CO2 incubator.
Twenty-four hours after seeding, the cells were treated with
sublethal concentrations of MnCl2 (100mM) or H2O (blank) for
5 hr. They were then suspended in HES buffer (20 mM HEPES
[pH 7.4], 1 mM EDTA, 250 mM sucrose, protease inhibitor cocktail
[RocheMolecular Biochemicals]) and homogenated by sonication.
After spindown at 100,000 g for 20 min at 4C, the pellet was
resuspended in HES buffer, and the protein concentration was
determined by using the bicinchoninic acid (BCA) protein assay
kit (Pierce) according to the manufacturer’s instructions. The
protein samples (80 mg) were separated by 6%–12% Criterion XT,
4%–12% Bis-Tris Gel (Bio-Rad) and then transferred to nitrocellu-
lose membranes. Membranes were blocked with 5% low-fat milk
powder (Fluka) in 13 PBS containing 0.1% Tween 20 (PBST) for
1 hr at room temperature and incubated overnight at 4C with
goat polyclonal antibody against SLC30A10 (Santa Cruz, 1/500)
and mouse monoclonal against actin (Sigma, 1/2,000). After
washing three times with PBST, the membranes were incubated
in the dark for 1 hr with PBST containing donkey anti-goat or
anti-mouse secondary antibodies (700 nm or 800 nm, LI-COR
Biosciences Lincoln, 1/5,000 dilution). After washing, the mem-
branes were scanned with the Odyssey Infrared Imager (Li-COR
Biosciences).
RT-qPCR Studies
HepG2 cells were cultured as mentioned before. Twenty-four
hours after seeding, HepG2 cells were treated with sublethal con-
centrations of MnCl2 (200 mM), ZnCl2 (100 mM), or buffer (blank)
for 5 hr. After treatment, cells were harvested, and total RNA was
isolated with RNAzol B (Cinna/Biotecx). Complementary DNA
(cDNA) was prepared from approximately 200 ng total RNA with
IScript cDNA synthesis kit (Bio-Rad) in a total volume of 40 ml
following the manufacturer’s instructions. For RT-qPCR experi-
ments, SLC30A10 and YWHAZ expression were compared to the
expression of a reference gene, TBP. Specific primers used are
reported in Table S1. Two assays were designed for SLC30A10
(termed SLC30A10_Q1 and SLC30A10_Q2). Both RT-qPCR assays
were validated by the demonstration of linearity over two orders
of magnitude and by observation of a single melt peak by plottingily. In individual NIJ005, marked hyperintensities are present in
e [H]); in individual NIJ010, T1-weighted images obtained around
normal levels showed no obvious abnormalities (axial image
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Table 1. Clinical and Biochemical Findings in Individuals with SLC30A10 Mutations
Individual Code
SIE-02 SIE-03 NIJ005 NIJ010 NIJ012
Gender male male male male female
Age (last examination,
years)
59 60 63 65 46 a
Presentation neurologic neurologic neurologic neurologic neurologic/hepatic
Symptoms onset (years) 47 57 2 14 10
Blood Mn levelsb (unit
of measurement); normal
range
104.0 (mcg/l); 3.0–8.0 106(mcg/l); 3.0–8.0 231.6 (nmol/l); <32.8 2626 (nmol/l); 183–352 n.a.
Polycythemia þ þ þ þ þ
Dystonia - - þ þ -
Parkinsonism þ þ - - -
Hepatomegaly þ þ - - þ
Liver ultrasound steatosis hyperplasia normal normal n.a.
Liver biopsy n.a. n.a. n.a. n.a. cirrhosis
Liver serum parameters normal normal normal normal n.a.
MRI-T1 abnormalities þ þ þ þ n.a.
Unremarkable
investigations




The following abbreviations are used: n.a., not available; EEG, electroencephalogram; MRS, brain magnetic resonance spectroscopy; EMG, electromyography;
ENG, nerve conduction studies; HV serology, negative serology for hepatitis A, B, and C; SPECT, brain ([123I]-FP-CIT) single photon emission computed tomog-
raphy of the dopamine transporter. A normal striatal uptake of this tracer indicates the integrity of the nigrostriatal dopaminergic pathways.
aDeceased.
bThe Mn levels were measured by different laboratories and in different times in the different individuals. Thus, different units of measurement and normal ranges
are reported.relative fluorescence units (RFU) data with time (T) (d(RFU)/dT)
on the y axis as a function of temperature on the x axis. Reactions
(15 ml) contained 200 nM primer, 1X KAPA SYBR FAST qPCR
Master Mix, and 0.5 ml cDNA. All reactions were performed in trip-
licates on a Bio-Rad CFX96 Real-Time System with the following
cycle conditions: 3 min initial denaturation at 94C followed by
30 cycles of 5 s each at 94C denaturation and 30 s 60C primer
annealing, extension, and RFU data collection. Data were analyzed
with CFX Manager Software V1.5 (Bio-Rad). Statistical analysis
with TBP/SLC30A10 and TBP/YWHAZ DCt values from each
sample was done via one-way analysis of variance ([ANOVA] Tukey
Honestly Significant Difference [HSD] test).
In Silico Analyses
The transmembrane regions in SLC30A10 and their orientation
in the membrane were predicted with the TMHMM Server v. 2.0
and the TMpred program. The closest SLC30A10 homologs were
identified by blasting the human sequence with the BLASTp pro-
gram. Retrieved sequences were saved in FASTA format and aligned
with the program ClustalW. GenBank accession numbers for the
SLC30A1 and SLC30A10 homologs are reported in the Table S2.Results
Clinical Studies
The most important clinical features are summarized in
Figure 1 and Table 1. In the Italian family, two brothers,470 The American Journal of Human Genetics 90, 467–477, March 9born from healthy first cousins, developed adult-onset
parkinsonism, hypermanganesemia, polycythemia, and
chronic liver disease. The proband (individual SIE-03,
IV-1 in Figure 1A), a 60-year-old man, was referred because
of a 3 year history of progressive gait disturbances and
bradykinesia. Treatment with pramipexole (1.05 mg/day)
had failed to improve parkinsonism. His past history
revealed he developed thrombocytopenia and polycy-
themia in his 30s. Our neurological examination showed
moderate hypomimia, monotone speech, moderate upper
limbs bradykinesia, and mild rigidity (more severe on the
right than on the left), global bradykinesia, wide-based
gait with freezing and starting hesitation, and moderate
postural instability (Movie S1). There was no evidence of
tremor, dystonia, or cerebellar or pyramidal disturbances.
The Unified Parkinson Disease Rating Scale13 motor score,
part III (UPDRS-III) was 27 (maximum 108). Aside from
polycythemia (red cell count 6.28 3 1012/mmc, normal
range [n.r.] 4.10–5.80) and mild thrombocytopenia
(136 3 109/mmc, n.r. 150–400) routine blood tests (in-
cluding liver functions parameters) were unremarkable.
Abdominal ultrasound showed hepatomegaly with liver
steatosis and splenomegaly. Alcohol consumption or
high-fat diet were not referred. Electrophysiological inves-
tigation showed a sensory-motor axonal polyneuropathy.
T1-weighted brain magnetic resonance imaging (MRI), 2012
Table 2. Clinical and Biochemical Follow Up in Individual SIE-03
during Monthly 5 Day Courses of Chelation Therapy with Disodium






Test, 3 m (s)
Baseline 1.06 106.0 27 18
Month 1 30.0 133.0 13 13
Month 2 76.0 101.0 10 10
Month 3 216.0 90.0 9 10
Month 4 219.0 4.2 8 8
UPDRS-III is an abbreviation for Unified Parkinson Disease Rating Scale, part III
(motor score). Higher scores correspond to more severe parkinsonism; the
maximum score is 108.showed bilateral, symmetrical hyperintensies at the level
of the caudate and lentiform nuclei, thalamus, cortico-
spinal tract, medial cerebral peduncle, substantia nigra,
posterior pons, and bulbar olives (Figures 1B, 1D, and 1E).
Plasma ceruloplasmin and urinary copper excretion
were normal, whereas plasma copper was slightly in-
creased (1317.79 mcg/l, n.r. 500–1250). Increased blood
transferrin (545 mg/dl, n.r. 200–360) and decreased ferritin
(16 ng/ml, n.r. 30–400) were also found. Blood and uri-
nary manganese concentrations were markedly increased
(106 mcg/l, n.r. 3.0–8.0; 16.0 mcg/l, n.r. 0.5–4.0). Also,
muscle manganese content was elevated (0.73 mcg/g;
normally undetectable). All possible sources of manganese
exposure were excluded. A 5 day course of disodium
calcium edetate infusion at a dose of 20 mg/kg twice daily
yielded a marked increase of urinary levels of manganese,
whereas the blood manganese increase persisted. A clear
improvement of the extrapyramidal symptoms was also
observed, and the UPDRS-III score decreased from 27 to
13 (Movie S2). This individual was therefore started on
monthly 5 day courses of chelation therapy with dis-
odium calcium edetate. After 4 months of treatment, man-
ganese urinary excretion was still markedly elevated
(219.0 mcg/l, n.r. 0.5–4.0) and blood manganese levels re-
turned to the normal range (4.2 mcg/l, n.r. 3.0–8.0). Serial
neurological evaluation showed progressive improvement
in gait, bradykinesia, and posture. The UPDRS-III score at
the 5 month follow up was 5/108 (Movie S3). Chelation
therapy was well tolerated and did not alter renal function
parameters. Longitudinal clinical and biochemical data in
this individual are summarized in the Table 2.
The younger brother (individual SIE-02, IV-2 in
Figure 1A) was a 59-year-old man presenting with a 12
year history of gait difficulties, postural instability with
frequent falls, and hypomimia. Polycythemia was diag-
nosed 2 years earlier. Neurological symptoms did not
improve after administration of levodopa/carbidopa
(100 þ 25 mg, twice a day). On admission, a neurological
examination showed mild hypomimia, slurred speech, a
wide-based gait with freezing and festination, and postural
instability. Formal UPDRS scoring was not applicableThe Amebecause of the marked genu recurvatum that severely
invalidated gait and posture. Routine blood tests confirmed
polycythemia (red cell count 5.95 3 1012/mmc, normal
range 4.10–5.80). An abdominal ultrasound showed mild
hepatomegaly with hepatic nodular hyperplasia but no
splenomegaly. Alcohol consumption and high-fat diet
were not referred. A T1-weighted brain MRI showed
bilateral, symmetrical signal hyperintensies with the same
distribution as was seen in his brother (Figures 1C and
1F). Markedly increased blood and urinary manganese
concentrations (104.0 mcg/l, n.r. 3.0–8.0 and 6.5 mcg/l,
n.r. 0.5–4.0, respectively) were found. Manganese content
in the muscle was also elevated (0.82 mcg/g, normally
absent). Chelation therapy (disodium calcium edetate)
was also startedwith referred clinical improvementwithout
side effects. However, detailed longitudinal data could not
be collected because this individual refused follow-up
examination.
In the Dutch family, three siblings born from
healthy first cousins all suffered from polycythemia from
early childhood, requiring regular phlebotomies. In the
oldest brother (individual NIJ010, IV-1 in Figure 1G),
now 65 years old, neurological problems started at age 14
when he experienced painful limb spasms on walking.
Over the years, he developed generalized dystonia and
became wheelchair dependent. Except for dystonia, the
neurological examination at age 63 showed no other
abnormalities (Movie S4). He was recently also diagnosed
with multiple myeloma (Kahler’s disease) (MIM 254500),
a common hematologic malignancy. His liver function
and liver and spleen ultrasound were normal. Of note,
only a borderline increase of manganese blood levels was
reported at recent evaluations (41.7 nmol/l, n.r. < 32.8),
and a brain MRI showed no gross abnormalities (Figure 1I).
However, markedly increased manganese levels (up to
2626 nmol/l, n.r. 183–352) were documented in the past.
Iron levels were normal, whereas total iron binding
capacity was mildly elevated (101 mmol/l, n.r. 45–80).
In his younger brother (individual NIJ005, IV-3 in
Figure 1G), now 63 years of age, walking difficulties
became apparent at the age of 2. Progressive dystonia led
to wheelchair dependency at the age of 34. Manganese
levels were severely elevated (231.6 nmol/l, n.r. < 32.8).
Iron and ferritin levels were normal, whereas total iron
binding capacity was also mildly elevated (114 mmol/l,
n.r. 45–80). Liver function parameters were normal, as
was a liver ultrasound. Spleen ultrasound data were not
available. The brain MRI showed hyperintense changes of
the pallidus on T1-weighted images (Figure 1H). At the
age of 61, neurological examination showed a rather pure,
generalized dystonia except for some sequelae of a cervical
disc herniation, such as hypesthesia and weakness in
the C5–C6 district and an extensor plantar response on
the left. Currently, he is in a nursing home because of
alcohol-related cognitive and behavioral changes.
Their younger sister (individual NIJ012, IV-2 in Fig-
ure 1G) died at the age of 46 because of decompensatedrican Journal of Human Genetics 90, 467–477, March 9, 2012 471
liver cirrhosis, portal hypertension, splenomegaly, and
hepatic encephalopathy. Information about her neurolog-
ical conditions is limited. She developed gait difficulties at
the age of about 10. At the age of 35, the neurological
examination showed gait disturbance and leg sensori-
motor disturbances with absent tendon reflexes, without
clear documentation of dystonia. A liver biopsy at age 31
showed micro- and macronodular cirrhosis with deposi-
tions of metallic- and protein-bound copper. Manganese
levels have never been determined, and neuroimaging
was never performed.
Genetic Studies
High-density SNP-array genotyping revealed only one
locus in the genome, on chromosomal region 1q41-q42,
showing extended homozygosity in all the three studied
affected individuals (Figure 2 and Figures S1–S2). In
individual SIE-02 the homozygous region was flanked
by heterozygous SNPs at positions 204188482 and
238837410; in individual SIE-03 the homozygous region
was smaller and flanked by heterozygous SNPs at positions
214699571 and 238837450. The analysis of individual
NIJ005 narrowed down further the critical region to
12.1 Mb of homozygous sequence, flanked by heterozy-
gous SNPs at positions 215429271 and 227575528 and
containing 106 annotated genes.
To identify the disease-causing variant, we initially per-
formed a mutational analysis of the coding regions of all
of these 106 genes by exome sequencing in individual
NIJ005. However, this approach did not detect any homo-
zygous exonic or splice-site variants, which were not anno-
tated in dbSNP132 or in the 1000 Genomes Project, in the
106 genes located in the critical region (Table S3). In-
terestingly, one of these genes, termed solute carrier family
30, member 10 (SLC30A10), encodes a poorly character-
ized protein bearing homology to the SLC30 family of
zinc cation transporters (GenBank accession numbers
NM_018713.2 and NP_061183.2). Thus, SLC30A10 repre-
sented an excellent candidate for this phenotype because
the body levels of another divalent cation (manganese)
are severely altered in these individuals, which could be
because of a defect in the transport of manganese. Interest-
ingly, the inspection of the exome data in individual
NIJ005 revealed a very low coverage of the SLC30A10
exon 1 (a very GC-rich region) (Table S4).
We therefore undertook Sanger sequencing of the
SLC30A10 coding region. Other genes within the critical
region were not analyzed by Sanger sequencing. Different
homozygous mutations were detected in the affected
members of the Italian and Dutch families and predicted
to lead to frameshift and premature protein truncation
(Figure 2). In the Dutch individuals NIJ005 and NIJ010
(IV-3 and IV-1 in Figure 1G), a homozygous c.507delG
mutation is present in exon 1, predicted to cause frame-
shift for 21 amino acids, followed by a premature stop at
codon 191, thereby removing a large portion (295 amino
acids) of SLC30A10 (p.Pro170Leufs*22). In addition, these472 The American Journal of Human Genetics 90, 467–477, March 9individuals also carry a homozygous substitution in
exon 1, c.500T>C, encoding the p.Phe167Ser alteration re-
sulting from the missense mutation in SLC30A10. In the
Italian affected individuals SIE-02 and SIE-03 (IV-2 and
IV-1 in Figure 1A), a homozygous c.1235delA mutation is
present in exon 4 and predicted to cause a frameshift for
25 amino acids, followed by a premature stop at codon
437 that removes the last 49 amino acids of SLC30A10
(p.Gln412Argfs*26). Unfortunately, DNA from the third
affected member in the Dutch family (NIJ012, IV-2 in
Figure 1G) and the unaffected parents in both families
was not available. Furthermore, RNA, which could be
used to test whether the mutant transcripts undergo
nonsense-mediated mRNA decay, was not available from
any members of the two families.
These mutations were not present in dbSNP132, the
1000 Genomes Project, or in the Exome Variant Server
database. We also tested 996 chromosomes from Italian
control individuals for the mutation found in the Italian
affected individuals, and 668 control chromosomes (294
Dutch and 374 Italian) for the mutations present in the
Dutch affected individuals. None of these mutations was
detected. Furthermore, only one additional heterozygous
variant was detected, in one Italian control individual
(c.1273G>A, predicted to lead to the p.Val425Ile alteration
resulting from the missense mutation, which is not ex-
pected to be pathogenic), highlighting a high conservation
of SLC30A10 coding sequence.
Immunohistochemistry Studies
SLC30A10 spans 14,388 nucleotides on chromosomal
region 1q41 (GenBank NM_018713.2). The principal tran-
script contains four exons for a total of 2,854 nucleotides,
and it encodes an ~52 kD protein of 485 amino acids,
SLC30A10. In humans, the highest levels of expression
of SLC30A10 mRNA are documented in the liver and the
central nervous system (CNS), but data concerning the
SLC30A10 protein are lacking. In order to characterize
the localization of SLC30A10, we performed immuno-
histochemistry in normal human liver and the central
nervous system and in the liver biopsy from one of the
Dutch affected individuals by using a commercially avail-
able polyclonal antibody (Figure 3). In the normal liver,
a punctuate pattern of immunoreactivity was detected in
the cytoplasm of the hepatocytes (Figure 3A) and in the
epithelium of bile ducts (Figure 3C); here, the plasma
membrane facing the lumen of the bile ducts was also
strongly immunoreactive. The above-mentioned staining
pattern is compatible with localization of SLC30A10 in
different compartments of the secretory pathway (in-
cluding the Golgi system, endosomes, and the plasma
membrane). Of note, immunoreactivity was almost absent
in the liver tissue from the affected individual (Figures 3B
and 3D), confirming the severe, deleterious effect of the
mutations. Also of note, in the nervous system, the stron-
gest immunoreactivity with similar cytoplasmic punctuate
pattern was detected in the neurons in the globus pallidus, 2012
Figure 2. Homozygosity Mapping and Detection of SLC30A10 Mutations
(A) Genome-wide SNP arrays scan defines one large homozygous region shared by the affected individuals from the Italian and the
Dutch families on chromosomal region 1q41-q42.
(B) Genomic organization of SLC30A10.
(C) Electropherogram showing the SLC30A10 mutations present in the Dutch affected individuals NIJ005 and NIJ010.
(D) Electropherogram showing the SLC30A10 mutation present in the Italian affected individuals SIE-02 and SIE-03.(Figures 3E and 3F). However, other neurons, such as the
motoneurons of the spinal cord were also immunoreactive
(Figure 3G).The AmeIn Silico and In Vitro Studies
SLC30A10 belongs to the cation diffusion facilitator (CDF)
superfamily of metal transporters. CDF proteins transportrican Journal of Human Genetics 90, 467–477, March 9, 2012 473
Figure 3. Localization of SLC30A10 in the Liver
and Nervous System
Immunohistochemistry was performed with an
anti-SLC30A10 antibody (Santa Cruz); the
images shown are from normal liver tissue (A
and C); a liver biopsy from the NIJ012 affected
individual (B and D); neurons from globus pal-
lidus (E and F) and spinal cord (G) of a normal
donor. In the liver, immunoreactivity is present
in the normal hepatocytes (A) and normal bile
ducts (C), but absent in the tissue from the
affected individual (B and D). The scale bars
represent 16.5 mm for all panels.divalent metal cations, such as iron, zinc, copper, nichel,
cobalt, manganese, and cadmium.14 Most CDF trans-
porters share a common topology, which is also predicted
for SLC30A10 by our in silico analyses, and consist of
six transmembrane domains (TMD), cytosolic N and C
termini, and a conserved C-terminal domain termed the
cation efflux domain (Pfam 01545) (Figure 4A). Most
CDF proteins function as antiporters, exchanging divalent
cations with Hþ or Kþ ions, and catalyzing the efflux of
metals from the cytosol to the extracellular space or to
subcellular organelles.15 Within the CDF superfamily,
zinc-specific transporters are more abundant and better
characterized than manganese-specific ones. SLC30A10
displays the highest homology to SLC30A1 (Znt-1),
a plasma membrane zinc transporter.16 However, we noted
that key structural features shared by known zinc trans-
porters14,17 are not present in SLC30A10 and its homologs
(Figure 4B). Indeed, the SLC30A1 group of zinc trans-
porters share two conserved HxxxD motifs (where x ¼
any amino acid) located in the TMD II and V and a histi-
dine-rich region, either in the cytosolic loop between474 The American Journal of Human Genetics 90, 467–477, March 9, 2012TMD IV and V or at the N or C termini. In
the human SLC30A10 and its homologs
in other species, the conserved histidine
in the HxxxD motif in TMD II is consis-
tently replaced by an asparagine. Moreover,
the histidine-rich region is absent, replaced
by a sequence rich in arginines, lysines, and
serines. Another CDF member, the plant
ShCDF8 protein from Stylosanthes hamata
known to be involved in manganese toler-
ance, also lacks the histidine-rich region.18
Conversely, some key features present in
other CDF members known to be involved
in manganese transport are consistently
present in the SLC30A10 cluster (Fig-
ure 4B).18 For example, a very conserved
cysteine residue at the cytosolic side of
TMD IV is characteristic of manganese-
specific transporters, and it is also consis-
tently present in the SLC30A10 cluster
(and not in the SLC30A1 cluster). These
arguments support strongly the contention
that SLC30A10 and its homologs differfunctionally from the zinc transporters and are specific
for a different cation substrate, most likely manganese.
The expression of several CDF transporters is under tran-
scriptional control by the concentration of their cation
substrate. For example, the expression of SLC30A1 (MIM
609521) is strongly induced by extracellular zinc.19,20 In
order to explore the mechanism regulating SLC30A10, we
exposed HepG2 hepatocellular carcinoma cells to sublethal
levels of manganese or zinc. After 5 hr of manganese expo-
sure, a marked 3-fold increase in the SLC30A10 mRNA
expression was detected (Figure 4C). Immunoblotting
analysis (Figure 4D) confirmed an increased abundance of
a band corresponding to the size of SLC30A10 (~52 kD).
Exposure to zinc led to a small decrease (~40%) in
SLC30A10 expression. These data document robust expres-
sion of SLC30A10 and the presence of the encoded protein
in human cells of hepatic origin, and, more importantly,
they show that the SLC30A10 is under tight control
by the extracellular manganese levels. Taken together,
our results provide, therefore, functional evidence that
SLC30A10 is a bona fidemanganese transporter inhumans.
Figure 4. In Silico Analysis of SLC30A10 and
In Vitro Expression Studies
(A) Schematic topology of SLC30A10. The pre-
dicted effects of the disease-causing mutations
are depicted.
(B) Alignment of the SLC30A10 and the SLC30A1
homologs.
(C) The expression of SLC30A10 is induced in
hepatocellular carcinoma cells (HepG2) after
exposure to sublethal concentrations of manga-
nese. The cDNA levels of the target gene
(SLC30A10) and those of an unrelated gene
(YWHAZ) are compared to those of a reference
gene (TBP). Two assays are performed for
SLC30A10 (Q1 and Q2) yielding similar results.
The data shown represent means 5 standard
error of the mean of experiments performed in
triplicates. The statistical analysis that used TBP/
SLC30A10 and TBP/YWHAZ DCt values from
each sample was done with one-way ANOVA
(Tukey HSD test). ***p < 0.001
(D) Immunoblotting analysis of HepG2 cells
shows increased abundance of a band of the
predicted size of SLC30A10 after exposure of the
cells to sublethal concentrations of MnCl2. Actin
is used as a loading control.Discussion
The discovery of two different homozygous, clearly delete-
riousmutations in a highly conserved protein that cosegre-
gate with disease in two independent families and are
absent in large numbers of control chromosomes estab-
lishes that the loss of the function of SLC30A10 is the
cause of this disease.
Detailed quantitative RT-PCR profiling in rodents docu-
mented that the highest expression of the SLC30A10
ortholog was in the liver, followed by the intestine, and
then by the CNS.21 In humans, there is evidence of expres-
sion of SLC30A10 in the liver, the CNS, and other organs in
both fetal and adult life (Unigene expressed sequence tag
profile at National Center for Biotechnology Informa-
tion).22 Furthermore, microarray data on the regionalThe American Journal of Hexpression of SLC30A10 in the human
brain are available online in the ALLEN Hu-
man Brain Atlas. In the Atlas, SLC30A10
expression levels are highest in the globus
pallidus, subthalamic nucleus, and deep
cerebellar nuclei and lower in the putamen
and other diencephalic and cortical areas,
whereas low expression levels are docu-
mented in the hippocampus and cerebellar
cortex. Our immunohistochemistry studies
in normal human liver and CNS provide
data on the localization of SLC30A10.
Furthermore, we document the dramatic
loss of the protein immunoreactivity in
the liver biopsy from one of the affected
individuals in the family with SLC30A10
mutations. These data are in substantialagreement with the mRNA expression profile data, and
taken together, they fit well with the profile of organs
involved in the metabolism of manganese (particularly
the liver) and with the phenotype associated with loss-of-
function mutations in the gene.
Manganese is an essential cation for the function of
several enzymes, including some crucially important for
the metabolism of neurotransmitters and other neuronal
metabolic pathways, such as glutamine synthetase, the
mitochondrial superoxide dismutase 2 (SOD2), arginase,
and pyruvate decarboxylase.2 Excessive levels of manga-
nese induce cell toxicity by a multitude of effects, in-
cluding competition with other cations for binding to
key proteins, effects at the level of DNA replication and
transcription, oxidative stress, interference with the mito-
chondrial oxidative phosphorylation, inhibition of theuman Genetics 90, 467–477, March 9, 2012 475
complex I, ATP depletion, and apoptotic cell death.1 There
is also evidence of direct effects of manganese excess on
different neurotransmitter systems, including GABAergic,
glutamatergic, and dopaminergic (also implicated in basal
ganglia dysfunctions, such as dystonia, and parkin-
sonism).1
Manganese levels in the body must therefore be tightly
regulated, and several transporters have been proposed to
play a role.1,2 Yet, the exact mechanisms of manganese
transport have not been conclusively determined. In
particular, a protein responsible for manganese efflux
from the cytosol has not been identified yet. Our findings
nominate SLC30A10 as a very important manganese trans-
porter in man and other species.
The high expression of SLC30A10 and its encoded
protein in the human liver is in keeping with a predicted
important role for this organ in the manganese homeo-
stasis.21 In individuals with homozygous loss-of-function
SLC30A10mutations, the manganese excretion is severely
defective, leading to metal accumulation in the liver, the
bloodstream, the brain, and other peripheral tissues. The
polycythemia is likely secondary to hypermanganesemia
because manganese is known to act on the erythropoietin
system in a manner similar to hypoxia,23 and polycy-
themia was reported to resolve after chelation therapy.10
The hypermanganesemia is by itself a cause of brain
toxicity, as shown in the persons with professional manga-
nese intoxications3 or those with chronic liver disease.4
However, in individuals with SLC30A10 mutations, we
speculate that the consequences of hypermanganese-
mia for the brain might be particularly severe because
SLC30A10 is also highly expressed in the brain, particu-
larly within the basal ganglia, probably to prevent the
neurotoxic effects of manganese excess there.
Thus, the metabolic signature in individuals with
SLC30A10 mutations is the extreme hypermanganesemia
with secondary polycythemia. Furthermore, the disease
leads to a variety of neurological or hepatic disturbances
that vary in severity and onset age, even within the
members of the same family. The neurological presenta-
tion ranges from juvenile-onset dystonia (in the Dutch
family reported here and a family reported previously)10
to late-onset akinetic-rigid parkinsonism (in the Italian
family reported here). Additional neurological pictures
might include juvenile-onset spastic paraparesis, as re-
ported previously in another individual.11 Interestingly,
the mutations present in our individuals with juvenile-
onset dystonia are predicted to have more deleterious
effects on SLC30A10 than themutations found in our indi-
viduals with late-onset parkinsonism (Figure 4A), suggest-
ing a possible source of genotype-phenotype correlation.
However, marked intrafamilial variability is also present.
Two of the three Dutch sibs had severe, generalized dysto-
nia, whereas the third had no obvious extrapyramidal
involvement. Also, liver cirrhosis eventually led to early
death in one of the Dutch sibs (neurologically the least
affected), but liver function was completely normal in476 The American Journal of Human Genetics 90, 467–477, March 9the other two. The Italian affected individuals had only
asymptomatic hepatic involvement detected by ultra-
sound. A similar wide variability in types of neurological
and hepatic presentation and clinical severity is character-
istic ofWilson’s disease (MIM 277900), a disorder of copper
transport.24 Whether the SLC30A10mutations, the hyper-
manganesemia, or both, played a role in the pathogenesis
of the multiple myeloma developed in individual NIJ010
(IV-1 in Figure 1G) remains unknown, but it cannot be
excluded.
Of note, chelation therapy was able to normalize the
manganese blood levels in the Italian individual and led
to dramatic clinical improvement of this otherwise poten-
tially lethal disease. Similar beneficial effects were previ-
ously reported in another individual.10 An early diagnosis
is therefore crucial, and genetic testing of SLC30A10 is war-
ranted in individuals with the neurological or hepatic
presentation, or in those with polycythemia, in combina-
tion with hypermanganesemia. Variability in SLC30A10
might also modulate susceptibility in subjects with pro-
fessional exposure to manganese, and further studies are
therefore warranted in this direction.
In conclusion, our identification of SLC30A10mutations
as the cause of this pleomorphic syndrome delineates it as
a primary disease of manganese metabolism and identifies
SLC30A10 as a critical regulator of the manganese trans-
port. Our findings have important implications for under-
standing the physiology of this essential metal and its
pathophysiology in disparate organs such as liver, blood,
and the nervous system.
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